Maze Therapeutics, Inc. MAZE 深 滬
已收盤 09-12 16:00:00 美东时间
23.295
-1.505
-6.07%
華盛通- 最 高25.48
- 今 開24.88
- 成交量 126.72万股
- 最 低 22.01
- 昨 收 24.80
- 總市值 10.22亿
- 52周最高 25.50
- 市盈率 靜 299.42
- 換手率 2.89%
- 52周最低 6.71
- 委 比 -88.59%
- 總股本 4385.09万
- 歷史最高 25.50
- 量 比 0.98
- 振 幅 13.99%
- 歷史最低 6.71
- 每 手 1
- 風險率
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股周涨跌榜 | 好莱坞或迎巨震！华纳兄弟探索频道周涨超55%；新思科技绩后暴跌28.9%
好莱坞或迎巨震！华纳兄弟探索频道周涨超55%，传Paramount Skydance拟收购公司；新思科技绩后暴跌28.9%>>
09-13 11:42
美股牛股 | 网红股OpenDoor一夜飙升近80%！公司高管团队调整
网红股OpenDoor一夜飙升近80%！公司高管团队调整；传埃里森家族正筹备收购，华纳兄弟探索频道大涨超29%>>
09-12 14:23
Maze Therapeutics Advances Clinical Programs Amid Financial Stability
Maze Therapeutics, Inc. ( ($MAZE) ) has released its Q2 earnings. Here is a bre...
09-12 11:57
Maze Therapeutics rises on $150M equity offering
Maze Therapeutics (NASDAQ:MAZE) shares rose over 45% premarket on Thursday after the biopharmaceutical company announced an oversubscribed private placement of its securities to raise gross proceeds o...
09-11 19:45
Maze Therapeutics Secures $150M In Oversubscribed Private Placement
Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced it has entered into a
09-11 19:37
Maze Therapeutics Reports Clinical Results From Phase 1 Healthy Volunteer Study Of MZE782, Oral Small Molecule Targeting Solute Transporter, SLC6A19
Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKDDose-dependent urinary amino acid excretion
09-11 19:33
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company, announced it has secured approximately $150 million through an oversubscribed private placement of securities. The transaction involved the sale of 4,000,002 shares of common stock at $16.25 per share and 5,231,090 pre-funded warrants at $16.249 each. Key investors include Frazier Life Sciences, Deep Track Capital, and others. Proceeds will fund the advancement of...
09-11 11:35
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
Maze Therapeutics announced positive Phase 1 results for MZE782, an oral SLC6A19 inhibitor targeting PKU and CKD. The study demonstrated excellent safety, tolerability, and robust target engagement in healthy volunteers. Dose-dependent increases in urinary phenylalanine (42-fold) and glutamine excretion were observed, supporting PKU treatment potential. A dose-dependent eGFR dip, similar to SGLT2 inhibitors, suggested potential kidney protective ...
09-11 11:30
BTIG Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $30
BTIG analyst Julian Harrison initiates coverage on Maze Therapeutics (NASDAQ:MAZE) with a Buy rating and announces Price Target of $30.
09-02 20:12
Maze Therapeutics names new finance chief
Maze Therapeutics (NASDAQ:MAZE) appointed Misbah Tahir as chief financial officer, effective immediately. Mr. Tahir brings more than 20 years of financial and strategic experience in the biopharmaceut...
09-02 19:32
